Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global chemotherapy-induced neutropenia market was valued at US$ 8.04 billion in 2021 and is expected to register a revenue CAGR of 5% to reach US$ 9.54 billion by 2030.

Chemotherapy-induced Neutropenia Market Fundamentals

Neutropenia caused due to chemotherapy is becoming a common side effect of chemotherapy treatments. Increased in the usage of chemotherapy in cancer treatment and availability of advanced techniques for the diagnosis of chemotherapy-induced neutropenia have resulted into a significant increase in the number of patients diagnosed with chemotherapy-induced neutropenia (CIN) in the past decade. Research indicates that chemotherapy-induced neutropenia is more commonly found in certain types of chemotherapies, such as alkylating agents and antimetabolites.

Patient characteristics, such as age and gender, may contribute to the development of chemotherapy-induced neutropenia. According to NCBI, most patients around 60 years of age are affected with chemotherapy-induced neutropenia. Therefore, physicians must be aware about the risk factors associated with chemotherapy-induced neutropenia to provide the best possible care to patients. 

[3473434]

Chemotherapy-induced Neutropenia Market Dynamics

The global chemotherapy-induced neutropenia market is expected to register high revenue growth during the forecast period from 2022 to 2030. This can be attributed to increased number of cancer patients receiving chemotherapy. According to the CDC (Centers of Disease Control and Prevention), over 1 million cancer patients in the U.S. get chemotherapy or radiation in an outpatient oncology clinic each year. Patients undergoing chemotherapy are vulnerable to infections, which can result in hospitalization, interruptions in chemotherapy schedules, and even death.

The global market for chemotherapy-induced neutropenia treatment is expected to be driven by increase in R&D activities by market players for the development of innovative medicines. For instance, in May 2022, the U.S. FDA approved Spectrum Pharmaceuticals eflapegrastim-xnst (Rolvedon) injection, which is used to minimize the possibility of infection, as expressed by febrile neutropenia, in adult patients with non-myeloid malignancies taking myelosuppressive anti-cancer medicines with a clinically significant incidence of febrile neutropenia.

The global chemotherapy-induced neutropenia market is significantly influenced by increase in government financing for life-threatening disorders. For instance, Macmillan, the cancer support charity, provides grants to adults and young people suffering from severe diseases. The grants are one-time contributions used to meet a variety of needs of these patients. Rise in awareness about cancer therapies and increase in the launch of new drugs are likely to fuel revenue growth in the market during the forecast period. 

However, the revenue growth of the market is likely to be constrained by delayed treatment due to the lack of awareness about the pathophysiology of a condition. 

Chemotherapy-induced Neutropenia Market Ecosystem

The global chemotherapy-induced neutropenia market is analyzed from three perspectives: treatment, distribution channel, and region.

Chemotherapy-induced Neutropenia Market by Treatment

[34242134]

Based on the treatment, the global chemotherapy-induced neutropenia market is segmented into antibiotic therapy and granulocyte colony-stimulating factor therapy. 

The antibiotic therapy segment accounts for the majority of the market revenue share. Fast action of antibiotics, easy availability, and the launch of novel products in the market are some factors increasing the segment’s revenue growth. In 2022, the U.S. FDA approved Eflapegrastim for the treatment of chemotherapy-induced neutropenia. This injection is intended for adult patients with non-myeloid malignancies who are being treated with myelosuppressive anti-cancer medicines that have been related to a clinically significant incidence of febrile neutropenia.

The granulocyte colony-stimulating factor therapy segment is expected to rise with a high CAGR in the coming years. The therapy encourages the bone marrow to produce white blood cells. The treatment can be a lifesaving option in many cases.

Chemotherapy-induced Neutropenia Market by Distribution Channel 

In terms of the distribution channel, the global chemotherapy-induced neutropenia market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. 

The retail pharmacies segment accounts for the leading position in the global market. This segment is expected to retain its dominance during the forecast period due to availability of a wide range of medications under the OTC category and preferences for self-medication. 

The online pharmacies segment is expected to register a significant CAGR between 2020 and 2030, due to rising internet usage and ease of buying pharmaceutical products through an e-commerce platform at better prices. 

Chemotherapy-induced Neutropenia Market by Region 

Regionally, the global chemotherapy-induced neutropenia market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America is leading the market in terms of revenue break-up. The U.S. determines the overall trends in the North America chemotherapy-induced neutropenia market due to high incidence of various cancers and increase in treatment administration in such patients. Furthermore, rise in funding from the public and private sector to mitigate the overall cost burden on the healthcare system has urged rapid innovation in the North America market. 

Despite the availability of preventive treatments in Europe, high number of patients are still affected by neutropenia. According to the NCBI, in 2022, drug-induced neutropenia occurs at a rate of 1.6 to 9.2 cases/million in Europe. Moreover, rising cancer prevalence, expanding healthcare infrastructure, and increased healthcare awareness are driving market revenue growth in this region.

Asia Pacific is expected to be a lucrative region for the market for chemotherapy-induced neutropenia treatment. Incidences of chemotherapy-induced neutropenia are observed in breast cancer patients from several countries in Asia Pacific. The respective cancer patients are commonly receiving docetaxel-containing regimens or dose-dense chemotherapy. According to a study conducted by Vanderbilt University School of Medicine, Nashville, patients who received dose-dense chemotherapy were more likely to experience severe neutropenia.

Chemotherapy-induced Neutropenia Market Strategic Developments

• In December 2021, a complete response letter (CRL) is received from the U.S. FDA for the New Drug Application (NDA) requesting approval of plinabulin combined with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia. The molecule belongs to BeyondSpring Pharmaceuticals, a multinational pharmaceutical company focused on the development of cancer therapeutics. 
• In June 2022, Pfizer received FDA approval for NYVEPRIA (pegfilgrastim-apgf), a Neulasta biosimilar (pegfilgrastim). NYVEPRIA is used to reduce the risk of infection, as shown by febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer medications that are linked with a clinically substantial risk of febrile neutropenia.

Chemotherapy-induced Neutropenia Market Competitive Landscape

The prominent players operating in the global chemotherapy-induced neutropenia market are:

• Teva Pharmaceutical Industries Ltd.
• Amgen, Inc. 
• G1 Therapeutics Inc.
• Kyowa Hakko Kirin Co., Ltd. 
• Novartis AG 
• Enzychem Lifesciences Corporation 
• BeyondSpring Pharmaceuticals Inc
• Hanmi Pharmaceutics Co. Ltd.
• Coherus Biosciences, Inc.
• Spectrum Pharmaceuticals Inc.

Frequently Asked Questions About This Report